Efficacy of cross-sectional imaging guided sympathetic neurolysis in abdoiniuopelvic tumors

To study the efficacy of visceral neurolytic blocks in the abdominopelvic cancer when guided by ultrasound/CT. 50 patients were selected randomly and prospectively from the pain clinic in NCI suffering from moderate-severe visceral pain (visual analogue score ≥ 4) due to advanced abdominal and pelvi...

Full description

Saved in:
Bibliographic Details
Published inEgyptian journal of radiology and nuclear medicine Vol. 49; no. 3; pp. 788 - 796
Main Authors Osman, Sarah Mamdouh, Mahmoud, Ikram Hamed, Riad, Rafaat Mahfouz, Shaaban, Mohamed Hamed
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.09.2018
SpringerOpen
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To study the efficacy of visceral neurolytic blocks in the abdominopelvic cancer when guided by ultrasound/CT. 50 patients were selected randomly and prospectively from the pain clinic in NCI suffering from moderate-severe visceral pain (visual analogue score ≥ 4) due to advanced abdominal and pelvic malignancy. Patients were divided into celiac plexus block-CPB (n = 25), superior hypogastric block-SHPB (n = 12) and ganglion impar block-GIB (n = 8) groups according to site of pain and then randomly and almost equally divided into subgroups of U/S and CT. Recording of baseline and postprocedure/follow up of visual analogue score (VAS), morphine consumption which constitute the primary outcome as well as patient global impression of change (PGIC) which represents the secondary outcome/quality of life. Complications at anytime during follow up were documented. There was significant (p < 0.001) reduction in post procedure VAS scores and morphine consumption after performing CPB and SHPB with satisfactory PGIC. Patients who performed GIB showed no significant change in pain scores or morphine consumption. There was a low complications rate with no major side effects. This study shows that guided sympathetic neurolytic blocks significantly reduce abdominal/pelvic cancer pain and analgesic consumption with no significant complications.
ISSN:0378-603X
DOI:10.1016/j.ejrnm.2018.05.003